All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Narendranath Epperla, Ohio State University, Columbus, US. We asked, How robust is POD24 (progression of disease within 24 months) as a predictor of survival in indolent lymphomas?
How robust is POD24 as a predictor of survival in indolent lymphomas?
Epperla begins by discussing the prognostic relevance of POD24, specifically in a multicenter U.S. based cohort study of patients with marginal zone lymphoma. He concludes that patients with POD24 had poorer outcomes compared with non-POD24 patients, outlining POD24 as an important clinical predictor of high-risk patients with follicular lymphoma or marginal zone lymphoma.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
FDA clears investigational new drug application for ‘OncoMimic’ based immunotherapy EO2463
On March 24, 2021, it was announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for EO2463, an...
FDA accelerated approval of umbralisib for R/R MZL and R/R FL
On February 5, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved umbralisib, a phosphoinositide 3 kinase-δ (PI3K-δ) and casein kinase 1-ε (CK1-ε) inhibitor,...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox